RxDoctor Payments Data

Joseph Amato, MD

Internal Medicine · Mobile, ALNPI 1417986050

Payments from drug & device makers

$4,180in general payments, 2019–2025

Across 305 payments — averaging $13.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$562
  • GSK$356
  • AbbVie$348
  • Amgen$328
  • Lilly USA, LLC$299
  • AstraZeneca$220
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,180100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,180 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$90,664
Medicare patients
135
Services billed
1,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$225,031
JardianceEmpagliflozin114$119,891
MounjaroTirzepatide76$105,895
FarxigaDapagliflozin Propanediol95$80,438
EliquisApixaban29$34,384
Tresiba Flextouch U-200Insulin Degludec32$31,906
TrulicityDulaglutide25$30,207
TradjentaLinagliptin25$24,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$24,586
MyrbetriqMirabegron21$22,364
LinzessLinaclotide22$21,407
Nurtec OdtRimegepant Sulfate16$20,024
KerendiaFinerenone14$17,195
VascepaIcosapent Ethyl20$16,598
Breo ElliptaFluticasone/Vilanterol18$15,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$562$225,031173 claims
Boehringer IngelheimJardiance, Tradjenta$122$144,765139 claims
Lilly USA, LLCMounjaro, Trulicity$299$136,102101 claims
AstraZenecaFarxiga, Symbicort$220$84,966110 claims
PfizerEliquis, Nurtec Odt$148$54,40945 claims
GSKTrelegy Ellipta, Breo Ellipta$356$39,58649 claims
Johnson & JohnsonInvokana, Xarelto$219$26,61941 claims
Astellas Pharma US IncMyrbetriq$119$22,36421 claims
AbbVieLinzess$348$21,40722 claims
BayerKerendia$168$17,19514 claims
MerckBelsomra$12$10,38619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →